STOCK TITAN

Citius Pharmaceuticals (CTXR) Stock News, Sep 2023-Feb 2024

CTXR NASDAQ

Citius Pharmaceuticals reports developments across its critical care and targeted oncology business, including activity at majority-owned subsidiary Citius Oncology. The company’s recurring updates center on LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.

Company news also covers LYMPHIR commercialization, U.S. launch progress, international access through Named Patient Programs, and investigator-initiated oncology studies involving gynecologic cancers and diffuse large B-cell lymphoma. Capital updates include registered direct offerings, warrant issuances, non-dilutive funding and other financing actions that support product commercialization and development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.51%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.77%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.90%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.90%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.36%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
management

FAQ

What is the current stock price of Citius Pharmaceuticals (CTXR)?

Citius Pharmaceuticals (CTXR) last closed at $0.5107.

What is the market cap of Citius Pharmaceuticals (CTXR)?

The market cap of Citius Pharmaceuticals (CTXR) is approximately $14.0M.